Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Accumulated Expenses (2016 - 2026)

Akebia Therapeutics has reported Accumulated Expenses over the past 11 years, most recently at $121.7 million for Q4 2025.

  • Quarterly Accumulated Expenses rose 91.8% to $121.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $121.7 million through Dec 2025, up 91.8% year-over-year, with the annual reading at $121.7 million for FY2025, 91.8% up from the prior year.
  • Accumulated Expenses was $121.7 million for Q4 2025 at Akebia Therapeutics, up from $106.4 million in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $144.7 million in Q3 2021 and troughed at $51.1 million in Q1 2023.
  • The 5-year median for Accumulated Expenses is $83.7 million (2022), against an average of $86.0 million.
  • Year-over-year, Accumulated Expenses tumbled 55.29% in 2023 and then surged 103.81% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $109.0 million in 2021, then plummeted by 30.49% to $75.8 million in 2022, then fell by 10.61% to $67.7 million in 2023, then decreased by 6.31% to $63.5 million in 2024, then soared by 91.8% to $121.7 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Accumulated Expenses are $121.7 million (Q4 2025), $106.4 million (Q3 2025), and $91.6 million (Q2 2025).